Evidence map›Paper›PMID 32770420›Full record

ReviewCurrent cardiology reports2020

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist.

Kershaw V Patel, Ashish Sarraju, Ian J Neeland, Darren K McGuire

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. DPP4 as a Potential Candidate in Cardiovascular Disease.Journal of inflammation research · 2022
    Review
  4. Insulin Resistance the Hinge Between Hypertension and Type 2 Diabetes.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Kershaw V PatelDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8830, USA.
Ashish SarrajuDivision of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Ian J NeelandDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8830, USA.
Darren K McGuireDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390-8830, USA. Darren.McGuire@UTSouthwestern.edu.ORCID 0000-0002-6412-7989
The University of Texas Southwestern Medical Center · USCardiovascular Institute of the South · USSouthwestern Medical Center · US

Funding

Visceral Adiposity and Diabetes: Translating Form to Function Using ImagingK23DK106520 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI NEELAND, IAN JASON · 2015 to 2019
$776k
NIDDK NIH HHS K23 DK106520
6 · The paper itself

Abstract

purpose of reviewResults from cardiovascular (CV) outcome trials have revealed important insights into the CV safety and efficacy of glucose-lowering agents, including dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). RECENT

findingsAmong patients with T2DM, DPP-4i have no significant effect on risk of major adverse CV events (MACE: CV death, myocardial infarction, or stroke) with mixed results regarding risk for heart failure (HF). While sitagliptin and linagliptin have neutral effects on HF risk, saxagliptin significantly increases the risk of HF. The CV safety of the GLP-1RA class of medications has been clearly demonstrated, and select agents, such as liraglutide, semaglutide, albiglutide, and dulaglutide, reduce the risk of MACE in patients with T2DM and established CV disease. CV outcome trials have demonstrated CV safety but not incremental efficacy for DPP-4i in most cases. Select GLP-1RA have proven efficacy for MACE and should be considered by cardiologists for CV risk mitigation in the care of patients with T2DM and established CV disease.

Indexed as

CardiologistsCardiovascular DiseasesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesGlucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsAtherosclerotic cardiovascular diseaseDipeptidyl peptidase-4 inhibitorsGlucagon-like peptide-1 receptor agonistsHeart failureType 2 diabetes mellitus

Identifiers

PMID32770420
OpenAlexW3047906356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.